Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic Failure

DSpace/Manakin Repository

Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic Failure

Citable link to this page

. . . . . .

Title: Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic Failure
Author: van Poll, Daan; Suganuma, Kazuhiro; Parekkadan, Biju; Carter, Edward Albert; Tilles, Arno W.; Yarmush, Martin Leon

Note: Order does not necessarily reflect citation order of authors.

Citation: Parekkadan, Biju, Daan van Poll, Kazuhiro Suganuma, Edward A. Carter, François Berthiaume, Arno W. Tilles, and Martin L. Yarmush. 2007. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS ONE 2(9): e941.
Full Text & Related Files:
Abstract: Modulation of the immune system may be a viable alternative in the treatment of fulminant hepatic failure (FHF) and can potentially eliminate the need for donor hepatocytes for cellular therapies. Multipotent bone marrow-derived mesenchymal stem cells (MSCs) have been shown to inhibit the function of various immune cells by undefined paracrine mediators in vitro. Yet, the therapeutic potential of MSC-derived molecules has not been tested in immunological conditions in vivo. Herein, we report that the administration of MSC-derived molecules in two clinically relevant forms-intravenous bolus of conditioned medium (MSC-CM) or extracorporeal perfusion with a bioreactor containing MSCs (MSC-EB)-can provide a significant survival benefit in rats undergoing FHF. We observed a cell mass-dependent reduction in mortality that was abolished at high cell numbers indicating a therapeutic window. Histopathological analysis of liver tissue after MSC-CM treatment showed dramatic reduction of panlobular leukocytic infiltrates, hepatocellular death and bile duct duplication. Furthermore, we demonstrate using computed tomography of adoptively transferred leukocytes that MSC-CM functionally diverts immune cells from the injured organ indicating that altered leukocyte migration by MSC-CM therapy may account for the absence of immune cells in liver tissue. Preliminary analysis of the MSC secretome using a protein array screen revealed a large fraction of chemotactic cytokines, or chemokines. When MSC-CM was fractionated based on heparin binding affinity, a known ligand for all chemokines, only the heparin-bound eluent reversed FHF indicating that the active components of MSC-CM reside in this fraction. These data provide the first experimental evidence of the medicinal use of MSC-derived molecules in the treatment of an inflammatory condition and support the role of chemokines and altered leukocyte migration as a novel therapeutic modality for FHF.
Published Version: doi:10.1371/journal.pone.0000941
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978513/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4621714

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters